Medpace Holdings, Inc.
No enriched coverage for $MEDP in the last 7 days.
Medpace Holdings CEO and President J. Troendle sold 7,238 shares of MEDP for about $4.35M, according to a July 29 Form 4 filing with the SEC. The article also cites MEDP revenue growth of 17.24% over the three months ended June 30, 2026, and a debt-to-equity ratio of 0.28. MEDP shares were about $574.55, down 2.51% Thursday morning.
Troendle August J. (President & CEO) sold 7,238 shares of Medpace Holdings, Inc. (MEDP) at an average of $600.44 ($600.01–$600.85, $4.35M total) across 2 trades over 2026-07-27 to 2026-07-28.
BURWIG SUSAN E (Exec. VP, Operations) sold 7,500 shares of Medpace Holdings, Inc. (MEDP) at $600.00 ($4.50M total) on 2026-07-28.
Recent MEDP coverage spans earnings, market movers and financial news.
In the last 30 days, MEDP insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($8.8M). The most active reporter was Troendle August J., President & CEO, with 2 filings.
The article provides a fresh insider-sale datapoint that can shift near-term sentiment, though it is not a fundamental change by itself.
Insider open-market selling by the CEO is a modest sentiment signal, but it is not tied to a new operational or financial catalyst in the filing.
This is a routine insider sale disclosure with no stated 10b5-1 plan, but it does not provide new operating or financial guidance.
Valuation framing is mixed: DCF implies modest undervaluation, but the earnings-multiple screen flags overvaluation versus a tailored fair P/E.
Forecast raise tied to improved net book-to-bill and backlog suggests demand durability for Medpace’s CRO services, supporting estimates upward.
alphai scores every news story that mentions MEDP with an AI model for sentiment and relevance, and aggregates insider trades from Medpace Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medpace Holdings CEO and President J. Troendle sold 7,238 shares of MEDP for about $4.35M, according to a July 29 Form 4 filing with the SEC. The article also cites MEDP revenue growth of 17.24% over the three months ended June 30, 2026, and a debt-to-equity ratio of 0.28. MEDP shares were about $574.55, down 2.51% Thursday morning.
3 min readTroendle August J. (President & CEO) sold 7,238 shares of Medpace Holdings, Inc. (MEDP) at an average of $600.44 ($600.01–$600.85, $4.35M total) across 2 trades over 2026-07-27 to 2026-07-28.
1 min readBURWIG SUSAN E (Exec. VP, Operations) sold 7,500 shares of Medpace Holdings, Inc. (MEDP) at $600.00 ($4.50M total) on 2026-07-28.
1 min readSimply Wall St says Medpace Holdings (MEDP) trades near about $601 after a 5-year 242% return. Using a DCF based on ~$706.3M free cash flow, intrinsic value is estimated at ~$654 per share, about 8% higher. The article also cites a P/E of ~34.2x versus a tailored fair P/E of ~20.7x, implying earnings-multiple overvaluation.
6 min readMedpace Holdings reported Q2 2026 revenue of $707.3 million, up 17.2% year over year, citing growth from small biopharma clients and expansion in Metabolic and Oncology. The company said its net book-to-bill improved to 1.13x and that backlog metrics supported raising its 2026 revenue forecast, according to the report.
1 min readZacks Investment Research reports Medpace Holdings (MEDP) hit a 52-week high of $677.9 and is up 16.5% over the past month. The firm says Medpace beat EPS and revenue consensus in each of the last four quarters, including July 22, 2026 results (EPS $4.25 vs $4.08; revenue 1.12% above). FY EPS is expected at $17.12 on $2.81 revenue.
6 min readMedpace (NASDAQ:MEDP) reported Q2 2026 revenue of $707.3M, up 17.2% YoY, with net new business awards rising 28.2% to $795.7M and a book-to-bill of 1.13x. Diluted EPS was $4.25. The company raised FY2026 guidance to revenue $2.805B-$2.885B and EBITDA $618M-$642M.
6 min readBiotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.
3 min readBiotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.
7 min readMedpace (MEDP) reported Q2 FY2026 revenue of $707.3M, up 17.2% YoY, with net book-to-bill of 1.13. Net income rose 34.5% to $121.4M, EPS was $4.25, and operating cash flow was $162M. Backlog ended at $3.0B. FY2026 guidance raised to revenue $2.805–2.885B and EPS $17.25–$17.95.
6 min read
